Illumina (NASDAQ:ILMN) Director Keith Meister Sells 75,951 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 75,951 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $218.23, for a total value of $16,574,786.73. Following the completion of the sale, the director owned 889,851 shares in the company, valued at approximately $194,192,183.73. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Illumina Stock Down 1.6%

Shares of NASDAQ ILMN opened at $218.22 on Friday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. The stock has a market capitalization of $32.95 billion, a PE ratio of 40.71, a P/E/G ratio of 3.14 and a beta of 1.46. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81. The business’s fifty day moving average price is $198.42 and its 200-day moving average price is $159.03.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same quarter last year, the firm posted $1.19 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently issued reports on ILMN. TD Cowen boosted their price target on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Stifel Nicolaus lifted their price objective on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Illumina in a report on Monday. Sanford C. Bernstein restated a “market perform” rating and set a $215.00 target price on shares of Illumina in a research report on Friday, July 31st. Finally, Leerink Partners raised their price target on Illumina from $175.00 to $210.00 and gave the stock an “outperform” rating in a report on Friday, July 17th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $191.31.

Trending Headlines about Illumina

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Argus raised its price target for Illumina (ILMN) from $180 to $235 and upgraded the stock to “buy,” implying additional upside from recent levels. The bullish view reflects confidence in Illumina’s earnings outlook and continued demand for genomic sequencing.
• Neutral Sentiment: Broader biotechnology coverage was mixed. 10x Genomics’ strong rally, supported by consumables growth and improved guidance, highlights investor interest in life-sciences tools, although weak instrument demand and valuation concerns remain sector risks. 10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
• Neutral Sentiment: Articles about robotics and AI-focused ETFs may support long-term interest in technology and automation themes, but they do not represent a direct catalyst for Illumina’s business or stock. Are Robots the New Normal? Bet on these ETFs to Invest in the Future
• Negative Sentiment: Zacks Research downgraded ILMN from “strong buy” to “hold.” The change introduces caution after the stock’s substantial advance and suggests that current valuation and expectations may leave less room for execution missteps. Illumina Analyst Downgrade
• Negative Sentiment: PacBio’s reduced 2026 outlook, attributed to weaker instrument demand and slower clinical adoption, is a modest negative read-through for the sequencing market. Although PacBio is a competitor rather than an Illumina subsidiary, the update raises questions about the pace of demand across the industry. PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test

Hedge Funds Weigh In On Illumina

A number of large investors have recently modified their holdings of the company. HighPoint Advisor Group LLC grew its stake in Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after acquiring an additional 80 shares in the last quarter. Elevation Wealth Partners LLC lifted its stake in Illumina by 52.5% in the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after purchasing an additional 84 shares in the last quarter. Meeder Advisory Services Inc. boosted its holdings in Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after purchasing an additional 85 shares during the period. Toronto Dominion Bank boosted its holdings in Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock valued at $4,407,000 after purchasing an additional 92 shares during the period. Finally, Panagora Asset Management Inc. grew its position in shares of Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after purchasing an additional 96 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.